Healthcare Industry News: blood glucose monitor
News Release - June 12, 2006
Glucon Announces New Clinical Study Results of Aprise(TM) in a Poster Presentation at the American Diabetes Association's 66th Scientific Sessions, in Washington, D.C.Aprise is a Non-Invasive, Continuous blood glucose monitoring Device
BOULDER, Colo.--(HSMN NewsFeed)--June 12, 2006--Glucon Inc., developer of innovative continual blood glucose monitoring devices, announced the complete results of its recent clinical study of Aprise at the American Diabetes Association's 66th Scientific Sessions, in Washington, D.C., June 9-13, 06 The data are also published in the Scientific Sessions Abstract Book, the June supplement to the journal Diabetes.
Dr. Ram Weiss presented Glucon's poster, titled Non Invasive Continuous Glucose Monitoring - Results from the First 62 Subjects. The presentation is part of the Clinical Therapeutics/New Technology Glucose Monitoring and Sensing category, number 408-P in the Poster Session in the Exhibit Hall. Dr. Weiss is a senior pediatric endocrinologist at Hadassah - Hebrew University School of Medicine in Jerusalem.
"Of the personal, non-invasive, continual blood glucose technologies currently in development, Glucon's Aprise is the most advanced in the clinical investigation process," noted Glucon's CEO Dan Goldberger.
The analysis of the data generated by the 62 subjects included 979 pairs of reference values and prospective, sensor derived glucose determinations. The mean absolute relative difference (RAD) of the sample was 19.9% with a median RAD of 13.2%. The mean and median differences were both around -5 -6 mg/dl indicating a slight over estimation of the sensor. When all of the results were plotted using the Clarke error grid (figure 1), 66.5%, 28.1%, 1%,4.4% and 0% were within the A, B, C, D and E ranges respectively.
"When the three study protocols were analyzed separately, the mean RAD for the oral glucose tolerance tests and the meal tolerance tests was superior to the mean RAD of the glucose infusion studies (17% vs. 19% vs. 22% respectively). Similarly, the prevalence of range D errors in the Clark error grid was smaller in OGTTs vs. meal tolerance tests and glucose infusion studies (2.1% vs. 5% vs. 8.6% respectively)," said Dr. Weiss.
Aprise(TM) is intended for self monitoring diabetic patients. It is the only device able to read blood glucose levels directly from a blood vessel, without puncturing the skin, through the use of a novel Photoacoustic (optical and sound-based) technology, proven to be superior to optics alone. The reading can be updated every five minutes or faster, allowing patients to respond to real time information. Aprise also signals when glucose levels rise or fall beyond acceptable levels.
"The study data further supports earlier findings that Aprise performs favorably in comparison to conventional finger stick glucose monitoring devices. We are currently developing the next generation of Aprise, which will be even smaller, lighter weight and comfortable to wear," said Glucon President Ron Nagar.
Glucon (www.glucon.com) is developing a pipeline of automated, continual, blood glucose (sugar) monitoring devices for home and clinical use. Glucon was founded in 2000 by Israeli scientists including Company President Ron Nagar. The company's flagship product, Aprise, is currently undergoing extensive clinical trials. Seed financing was provided by InnoMed Ventures. Additional investors include Giza Venture Capital, Infinity Venture Capital Fund, Ascend Technology Ventures, and several others.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.